Results 121 to 130 of about 24,471 (215)
Michael Bröker, Brian Cooper, Lisa M DeTora, Jeffrey J StoddardGlobal Medical Affairs, Novartis Vaccines and Diagnostics, Marburg, Germany, and Cambridge, MA, USAAbstract: Worldwide, invasive meningococcal disease affects about 500,000 people ...
Bröker M +3 more
doaj
Meningococcal Vaccines: Challenges and Prospects. [PDF]
Bagwe P +5 more
europepmc +1 more source
Meningococcal vaccines and protein-energy undernutrition in children in the African meningitis belt. [PDF]
Sundaram ME +6 more
europepmc +1 more source
Economic evaluation of meningococcal vaccines: considerations for the future. [PDF]
Christensen H +17 more
europepmc +1 more source
Meningococcal vaccine. From capsular polysaccharides of microbes to proteases
Microbial capsular polysaccharides for many years provided a highly practical public health vaccines for preventing meningococcal, pneumococcal and Haemophilus influenza infection, and typhoid fever.
A P Alliluyev +12 more
doaj
Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib. [PDF]
Ishowo-Adejumo R +3 more
europepmc +1 more source
<i>Neisseria meningitidis</i> bacteraemia and lobar pneumonia in a previously healthy, fully immunised (including meningococcal vaccines) Irish teenager. [PDF]
Lacey S, Moylett E.
europepmc +1 more source
Meningococcal vaccines in Australia: a 2019 update. [PDF]
Sharma K, Chiu C, Wood N.
europepmc +1 more source

